Advaxis, Inc. (OTCMKTS:ADXS) Short Interest Down 27.5% in September
Advaxis, Inc. (OTCMKTS:ADXS) Short Interest Down 27.5% in September
Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) saw a large decrease in short interest in September. As of September 15th, there was short interest totalling 2,900 shares, a decrease of 27.5% from the August 31st total of 4,000 shares. Based on an average daily volume of 6,000 shares, the days-to-cover ratio is currently 0.5 days.
Advaxis，Inc.(場外交易代碼：ADXS-GET Rating)9月份空頭股數銷量大幅下降。截至9月15日，空頭股數共有2900股，比8月31日的4000股減少了27.5%。以日均成交量6,000股計算，目前天數與回補比率為0.5天。
Advaxis Stock Up 2.3 %
Advaxis股價上漲2.3%
ADXS opened at $2.21 on Friday. Advaxis has a fifty-two week low of $1.02 and a fifty-two week high of $44.80. The firm has a market cap of $4.00 million, a price-to-earnings ratio of -22.05 and a beta of 2.07. The stock has a 50-day simple moving average of $3.23.
ADXS上週五開盤報2.21美元。Advaxis的52周低點為1.02美元，52周高位為44.80美元。該公司市值為400萬美元，市盈率為-22.05倍，貝塔係數為2.07。該股的50日簡單移動均線切入位為3.23美元。
Analyst Ratings Changes
分析師評級發生變化
Separately, StockNews.com initiated coverage on shares of Advaxis in a research report on Monday, August 22nd. They set a "sell" rating on the stock.
另外，StockNews.com在8月22日星期一的一份研究報告中啟動了對Advaxis股票的報道。他們對該股設定了“賣出”評級。
About Advaxis
關於Advaxis
Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.
Advaxis，Inc.是一家臨牀階段的生物技術公司，專注於在美國發現、開發和商業化專有的單核細胞增生性李斯特菌(LM)技術抗原遞送產品。該公司正在開發ADXS-PSA，這是用於治療轉移性前列腺癌的第二階段臨牀試驗；ADXS-503，用於治療非小細胞肺癌；以及ADXS-504，用於治療前列腺癌。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- Humana Proves Vertically Integrated Healthcare Works
- What Cintas Can Teach Investors About This Bear Market?
- 2 Casino Stocks Worth Taking a Look At
- This Small-Cap Healthcare Name Is Outperforming Its Index
- Blackberry Stock Declines As Results Come In Lukewarm Once Again
- 免費獲取StockNews.com關於Advaxis的研究報告(ADXS)
- Humana證明垂直整合的醫療保健工作
- 關於這個熊市，Cintas能教給投資者什麼？
- 值得一看的2只賭場股票
- 這家小盤股醫療保健公司的表現好於其指數
- 黑莓股價下跌，業績再次不温不火
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.
接受Advaxis Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Advaxis和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。